Thursday, May 7, 2020
Investigator(s): Eric Daar, MD
LOS ANGELES (May 6, 2020) — Today, researchers at The Lundquist Institute began a randomized, double-blind, placebo-controlled clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in individuals suffering from COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. This trial, sponsored by the National Institutes for Health, will include 2,000 adults with symptomatic SARS-CoV-2 infections. Under the direction of Dr.